Drug manufacturers may face a deficit of raw materials as early as in spring.
St. Petersburg’s pharma manufacturers may have no raw materials for drugs left in stock due to coronavirus. According to RBC, a deficit can appear in spring already.
Due to the epidemics, many Chinese factories supplying up to 70% of substances used for drug manufacturing are closed. The stocks left over would last by the beginning of March only.
If the Chinese manufacturers do not resume supplies by then, St. Petersburg’s pharma companies will have to look for alternative suppliers elsewhere, probably, in Latin America, India and South Korea.
The problem is that the registration procedures for new suppliers are lengthy.